Navigation Links
Salmeterol - to be used in combination & only when required

Asthma experts at University of Iowa are taking efforts to make sure that an asthma drug combination is prescribed only when really needed.//

Salmeterol is a long-acting asthma drug that is used in combination with a corticosteroid, which is inhaled. The use of this combination can deteriorate the asthma for a few people with that condition.

The UI physicians reported two cases representing the few patients for whom the combination can make asthma more severe or even fatal in a letter published in the Aug. 24 issue of the New England Journal of Medicine (NEJM).

"For most patients whose asthma cannot be controlled with a low-dose inhaled steroid, adding salmeterol to the steroid provides increased benefits. So there's no question this can be a useful combination drug for many individuals," said Miles Weinberger, M.D., professor of pediatrics in the University of Iowa Roy J. and Lucille A. Carver College of Medicine.

"However, some patients are receiving the combination drug but don't actually need it, and there is at least a small subgroup of patients for whom previous research showed the salmeterol-steroid combination has a very negative, rather than beneficial, effect," said Weinberger, who also directs the UI Division of Pediatric Allergy and Pulmonary Diseases.

Advair, made by GlaxoSmithKine, contains salmeterol in addition to an inhaled corticosteroid and is extensively marketed, Weinberger said. It is one of the most commonly prescribed maintenance asthma medications in the United States and is meant to be used by patients on a regular, preventive basis, not to treat sudden asthma attacks.

"We do not want to unduly alarm people, but instead help spread the word that patients should talk with their physicians if they are using Advair, or another inhaled asthma medication that contains salmeterol and feel that it worsens symptoms instead of making them better," Weinberger said.

The UI physician s' letter follows up a related editorial published December 2005 in the NEJM by Fernando Martinez, M.D., a leading asthma expert. The letter also helps illustrate findings reported this year in a large, population-based study in the United States that is consistent with a previous study in England.

The U.S. study showed a very small, but statistically significant, increased risk of asthma-related deaths -- 13 among 13,000 individuals who received salmeterol but only three among another 13,000 individuals who received a placebo during a 28-week treatment period. Other studies have suggested that some people have a genetic variation that causes them to respond negatively to the class of medications that includes salmeterol, Weinberger said.

The concern about salmeterol and a related medication, formoterol, led the U.S. Food and Drug Administration this year to add a "black box" warning to products containing these medications.

The warning is appropriate, Weinberger said, but many people, including health care professionals, remain unaware of the problem. To raise awareness, Weinberger and Mutasim Abu-Hasan, M.D., UI clinical associate professor of pediatrics, documented two cases they saw at the UI that showed the risk of these medications.

Each of the two patients had life-threatening problems related to salmeterol use. When the patients switched to a different asthma medication, their asthma was successfully managed.

Weinberger emphasized that people currently taking asthma medication that contains salmeterol should continue taking it until they consult their physicians.

"For many patients, adding salmeterol to an inhaled corticosteroid provides additional clinical benefit. Patients should contact their physicians if they notice their response to a 'rescue' inhaler such as albuterol is lessened when they're taking salmeterol as part of a regular maintenance medication," he said.

Weinberger said th at many primary care physicians, partly in response to heavy drug marketing, immediately start patients on the combination drug instead of first trying the inhaled steroid alone.

"We want to build on Dr. Martinez's recommendation and encourage primary care physicians to start asthma patients on just the inhaled steroid as a regular maintenance medication and then add the salmeterol by using a combination product only if the person's asthma symptoms are not adequately controlled," Weinberger said.

Nearly 20 percent of all children have some degree of asthma. At least 6 percent of adults have asthma, as well.

It is not currently possible to test each patient with asthma to see if he or she has genetic risk factors for a bad reaction to Advair. The genetic testing is not commercially available, and all the genetic variations that could contribute to the problem are not yet known.

(Source: Eurekalert)
'"/>




Related medicine news :

1. Novel Anti-Neutrophilic Effect produced by Salmeterol in mild asthma patients
2. The bad combination
3. Warding off symptoms of premenstrual syndrome by combination therapy
4. Cholesterol can be lowered using combination of Soy Proteins and Sterols
5. Nanocells cancer combination therapy acts as chemotherapy as well as anti-angiogenic drug
6. Calcitriol [Vitamin D] with combination of painkillers for cancer treatment
7. Chloroquine and Primaquine combination Malarial drug for resistant parasites.
8. Eloxatin combination reduces bowel cancer recurrences
9. Death from heart attack can be reduced by new drug combination
10. New tetanus-diphtheria combination vaccine launched by Serum Institute of India
11. More effective Antiretroviral HIV drug combination
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/28/2017)... ... June 28, 2017 , ... Hayes, Inc., a leading provider ... guest speaker lineup* for its second annual Client Symposium. Joining the symposium this ... Keith Fernandez of Privia Health; and Lisa Tourville of Anthem. , “We ...
(Date:6/28/2017)... ... 2017 , ... The Wharton School’s Aresty Institute of Executive ... kick-off to the fifth annual CEO Connection Mid-Market Convention. , The Wharton ... campus, followed by the two-day convention, which will target C-suite executives in mid-market ...
(Date:6/28/2017)... ... June 28, 2017 , ... Schneider Insurance ... assistance to clients in southern Montana, is announcing a focused charity effort to ... The outreach programs offered by Zoo Montana provide students with current knowledge on ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... ... announced the appointment of Mike Finnegan to the position of Executive Vice President, ... of experience in healthcare technology, telehealth and medical device sales leadership. He has ...
(Date:6/27/2017)... ... June 27, 2017 , ... ... many of the health care industry’s hospitals and provider groups, has announced that ... for select customers. Parasail Health is a San Francisco health-finance startup that has ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... 2017 AirXpanders, Inc. (ASX: AXP) (AirXpanders or ... manufacture, sale and distribution of the AeroForm® Tissue Expander ... its commercial roll-out in the United States ... one hundred (100) medical institutions and health systems, located ... needle-free alternative for women who choose reconstructive surgery following ...
(Date:6/8/2017)... 2017  StatLab Medical Products ("StatLab" or ... of diagnostic supplies for the anatomic pathology ... Company LP ("Cressey & Company"), a healthcare-focused ... investment in the Company. Cressey & Company ... selling shareholder, Prairie Capital, L.P., with certain ...
(Date:6/5/2017)... The Cincinnati location of ... (NYSE: DPLO), has been awarded a Top Workplaces 2017 ... Results are based on an employee survey administered by WorkplaceDynamics, ... improvement. The survey measures several aspects of workplace culture, including ... ...
Breaking Medicine Technology: